Literature DB >> 8059735

Safety of combined pravastatin-gemfibrozil therapy.

R S Rosenson1, W A Frauenheim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8059735     DOI： 10.1016/0002-9149(94)90913-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  6 in total

Review 1.  Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Authors:  David Williams; John Feely
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.

Authors:  M Haria; D McTavish
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 3.  Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?

Authors:  Bijesh P Maroo; Carl J Lavie; Richard V Milani
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 4.  Myopathy with statin-fibrate combination therapy: clinical considerations.

Authors:  Terry A Jacobson
Journal:  Nat Rev Endocrinol       Date:  2009-07-28       Impact factor: 43.330

Review 5.  Combination lipid-lowering therapy in diabetes.

Authors:  Michael H Davidson
Journal:  Curr Diab Rep       Date:  2003-06       Impact factor: 4.810

Review 6.  Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.

Authors:  C M Spencer; L B Barradell
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.